ReviewFrontiers in plant science2025
Recent advances in site-specific transgene insertion into the maize genome using recombinases and genome editing endonucleases.
Review in Frontiers in plant science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in Genome Editing for Plant Disease Resistance Breeding.Plants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Random insertion of T-DNA into the maize genome requires the generation of many transgenic events, resulting in high cost and extensive development time. In contrast, site-specific transgene insertion (SSTI) in highly stable genomic regions emerges as an interesting and more viable alternative, as it allows obtaining elite lines in less time and effort. FLP/FRT and CRISPR/Cas9 homology-directed repair (HDR) strategies, as well as their combinations, are currently the most effective for SSTI in maize. The FLP/FRT system still depends on generating a high number of transgenic events, selecting a recombinant target line (RTL), and co-transforming this RTL with a second T-DNA, since there is no prior information on whether the insertion site is considered stable. In turn, CRISPR/Cas9 HDR requires prior information about the insertion site. From this principle, SSTI is effectively targeted by CRISPR/Cas9 HDR, requiring a smaller number of transgenic events. Furthermore, other strategies have been used for SSTI in animal cells and other plant species, and are very promising for establishment in maize as well. Herein, we highlight the importance of SSTI and the advances made in identifying genomic safe harbors in the maize genome. Furthermore, we emphasize the potential of the FLP/FRT system, CRISPR/Cas9 HDR, and CRISPR-associated recombinases and polymerases. We also offer insights into binary and ternary vector strategies, transgene delivery systems, maize tissue culture, and SSTI event genotyping. Finally, we highlight the importance of rigorous quality control for elite lines containing STTI. Therefore, this study provides insights and trends into SSTI in maize mediated by recombinases and genome editing endonucleases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.